CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

Inclusion Criteria

• •1. Age is 16 years old, less than 70 years old, sex is not limited, race is not limited;
• •2. The pathological diagnosis was CD19 positive expression of B type lymphoma relapsed / refractory, meet any one of the following can be diagnosed with relapsed / refractory lymphoma: 1）the standard scheme of standardized treatment of more than 4 courses in 50%, or the condition of tumor size;2） standard treatment of CR, but the recurrence of use the original scheme or the current national consensus recommended second-line treatment can not get CR again;3） the relapse after haematopoietic stem cell transplantation;
• •3. The patient needs to have a lesion that can be used to detect or evaluate the disease.
• •4. 0\~1 score of physical status score of the eastern cancer cooperation group (ECOG).
• •5. At the time of collection of peripheral white blood cell counts over 1 \* 10\^9/L;
• •6. Expected survival time \> 90 days;
• •7. Patients have the ability to know and sign informed consent.